The aim of our study was to determine the incidence of metabolic syndrome (MetS), the frequency and combination of its definitive components and gender differences in patients with ST segment elevation myocardial infarction using two criteria of diagnosis: The Russian Criteria For Diagnosis Of Metabolic Syndrome And The New Harmonized Definition Of Metabolic Syndrome. Among 112 patients that were included in the study, 67.8% of patients using the Russian criteria and 75.9% of patients using the new harmonized definition had metabolic syndrome. Using both criteria, patients with MetS were more likely to be females, were older than males and with higher body mass index (BMI). The most common combination of three components was AO+AH+ low HDL-C and the most common combination of four components was AH+ AO+HTG+low HDL-C. Results of the study demonstrated high prevalence of MetS among patients with ST segment elevation myocardial infarction, especially in females.

Aim. To determine the association between cardiovascular disease risk factors and presence of coronary arteries lesions with the involvement of left main coronary artery (LMCA). Methods. We included male and female patients 40-60 years old, who underwent coronary angiography: with coronary atherosclerosis and LMCA involvement — group 1 (n—83), with coronary atherosclerosis without any lesions in LMCA — group 2 (n—88), and patients with intact coronary arteries — group 3 (n—34). All patients identified Cardiovascular disease traditional risk factors as well as lipoprotein (a), interleukin-6, C-reactive protein serum levels were determined in all patients. Results. A percent of women was higher in group 3 compare to group 1 and group 2 (59% vs 17% p—0.00001 and 59% vs 16% p—0.00001, respectively), as well as a percent of smokers was lower (19% vs 44% p—0.03 and 19% vs 61% p—0.0001, respectively), as was expected. All patients were treated with hypolipidemic therapy, however the levels of high density lipoprotein was significantly lower in the group 1 compare to group 2 and group 3 (1.04+0.29 vs 1.2+0.49, p—0.04 and 1.04+0.29 vs 1.28+0.35, p—0.005, respectively). The levels of lipoprotein (a) were not significantly different between the groups. Serum interleukin-6 had a tendency to increase in the group 1 versus group 3 (4.31+5.24 vs 2.06+1.8, p—0.06, respectively).

Determination of association between risk factors for cardiovascular disease (CVD) and the lesions of coronary arteries with involving the left main coronary artery (LMCA). We studied male and female aged 40-60 years who performed coronary angiography: with stenosis of the coronary arteries including LMCA group 1(n = 83), without lesions of the LMCA – group 2 (n = 88), and patients with intact coronary arteries group 3 (n = 34). All patients identified traditional risk factors for CVD, and levels of Lp(a), IL-6, CRP. In the group 3 the number of women were significantly higher versus to groups 1 and 2 (59% vs 17% p=0.00001 and 59% vs 16% p=0.00001, respectively), as well as the number of smokers significantly lower in the same group (19% vs 44% p=0.03 and 19% vs 61% p=0.0001, respectively), as was expected. All patients were treated with hypolipidemic therapy, however the levels of HDL-C was significantly lower in the group 1 versus to groups 2 and 3 (1.04 ±0.29 vs 1.2 ±0.49, p=0.04 and 1.04 ±0.29 vs 1.28 ±0.35, p=0.005, respectively). The level of Lp(a) was not significantly different between the groups. Serum IL-6 had a tendency to increase in the group 1 versus to group 3 (4.31 ±5.24 vs 2.06 ±1.8, p = 0.06, respectively). We determined a lower levels of HDL-C and tendency to increase the level of IL-6 in patients with lesions of the LMCA compared with other groups.

Application of inhibitors of HMG-CoA reductase in patients with rheumatologic diseases is currently limited by hypercholesterolemia. The presence of rheumatic diseases in a patient does not included in current algorithms for assessing cardiovascular risk. This review provides information about additional factors of cardiovascular risk in patients with various rheumatologic diseases.

AIM To assess dynamics of marker of inflammation (C-reactive protein - CRP) and parameters of lipid metabolism at the background of 3-months course application of 2 standard variants of therapy with atorvastatin (40 and 10 mg/day) in patients with rheumatoid arthritis (RA) compared with patients with ischemic heart disease (IHD) with moderate hyperlipidemia. MATERIAL AND METHODS Patients of both sexes (n=64, 40 with IHD, 24 with RA, age from 45 to 60 years) with moderate hyperlipidemia and positive reaction to CRP were included into the study. Measures of efficacy of therapy with atorvastatin were percent changes of CRP, total (T) cholesterol (CH), and low density lipoprotein (LDL) CH compared with initial values. RESULTS Portions of patients with IHD and RA who achieved target LDLCH level < 2.6 mmol/l were 84 and 67% on atorvastatin 40 mg/day, 44 and 50% on atorvastatin 10 mg/day, respectively. Changes of blood serum concentrations of triglycerides and high density lipoprotein CH were insignificant in all groups. Most pronounced lowering of CRP took place in a subgroups of IHD patients with initially high CRP level (-20%) and patients with RA (-65%) to whom atorvastatin was prescribed in a dose of 40 mg/day. Changes in patients in other subgroups were not significant. CONCLUSION HMG-CoA-reductase inhibitor atorvastatin more effectively lowers concentration of CRP in blood plasma of patients with PA than with IHD what possibly is explained by higher initial level of this marker of inflammatory processes.

Aim. To assess the dynamics of an inflammatory marker, C-reactive protein (CRP), and lipid profile during 3-month high- and low-dose atorvastatin therapy (40 mg/d and 10 mg/d) in patients with rheumatoid arthritis (RA) or coronary heart disease (CHD) and moderate hyperlipidemia (HLP). Material and methods. The study included 64 male and female patients: 40 with CHD and 24 with RA, aged 45-60 years, with moderate HLP and positive CRP reaction. Atorvastatin therapy effectiveness was assessed by decrease in CRP, total cholesterol (TCH) and low-density lipoprotein CH (LDL-CH) levels, comparing to baseline concentrations. Results. During high- and low-dose atorvastatin therapy, 84% and 44% of CHD patients, respectively, achieved target LDL-CH levels (< 2,6 mmol/l). Among RA patients, these figures were 67916 and 50%, respectively. Triglycerides and high-density lipoprotein CH dynamics was insignificant in each group. Maximal reductionin CRP level was observed among CHD patients with initially elevated CRP concentration and RA patients receiving high-dose atorvastatin therapy (reduction by 20% and 65%, respectively); in all the other subgroups, CRP dynamics was insignificant. Conclusion. Statins reduced CRP concentration in RA patients more effectively than in CH D individuals, possibly, due to initially higher CRP levels among the former.

Inhibitors of the key enzyme of cholesterol biosynthesis beta-hydroxy-beta-methylglutaryl-coenzyme A reductase (statins) decrease cholesterol content in atherogenic low-density lipoproteins in patients with coronary heart disease and hypercholesterolemia, but inhibited biosynthesis of ubiquinone Q10 protecting low-density lipoproteins from free radical oxidation. Cerivastatin in a daily dose of 0.4 mg markedly increased the content of lipid peroxides in low-density lipoproteins. However, complex therapy with cerivastatin and antioxidant probucol (250 mg/day) was accompanied by a sharp decrease in the content of lipid peroxides in low-density lipoproteins in patients with coronary heart disease in vivo. These data indicate that antioxidant agents should be used in combination with inhibitors of beta-hydroxy-beta-methylglutaryl-coenzyme A reductase (hypolipidemic preparations) for the therapy of patients with coronary heart disease.

This study analyzed the effects of nutriceutic Adrusen Zinco containing vitamin E and prosthetic groups of antioxidant enzymes (selenium, copper, zinc) on the parameters of free radical oxidation of blood lipids in patients with coronary heart disease and hypercholesterolemia. Adrusen Zinco considerably increased activity of erythrocyte and serum selenic glutathione peroxidase as soon as after 1-month treatment, while erythrocyte SOD activity significantly increased only after 2 months.